UK court sends Pfizer/Flynn back to the CMA
The Court of Appeal of England and Wales has held that the UK’s competition enforcer did not sufficiently prove that two drug companies' prices were excessive, but backed the enforcer that it does not need to construct a hypothetical benchmark price.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.